# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001144204-17-053962
Filing Date
2017-10-25
Accepted
2017-10-25 08:00:22
Documents
8
Period of Report
2017-10-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM 8-K | tv477696_8k.htm | 8-K | 18442
2 | EXHIBIT 99.1 | tv477696_ex99-1.htm | EX-99.1 | 7583
3 | EXHIBIT 99.1 | tv477696_ex99-1.pdf | EX-99.1 | 536033
4 | EXHIBIT 99.2 | tv477696_ex99-2.htm | EX-99.2 | 7924
5 | EXHIBIT 99.2 | tv477696_ex99-2.pdf | EX-99.2 | 533890
6 | GRAPHIC | image_001.jpg | GRAPHIC | 5687
7 | GRAPHIC | ex99-1.jpg | GRAPHIC | 764357
8 | GRAPHIC | ex99-2.jpg | GRAPHIC | 754897
| Complete submission text file | 0001144204-17-053962.txt |  | 3609794

Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 171152090
SIC: 2834 Pharmaceutical Preparations